Fever-Tree revenue edges higher amid product diversification

Fever-Tree Drinks has reported a 4% increase in brand revenue at constant currency for the year to 31 December 2025, with momentum picking up in the second half as growth accelerated to 5%.

Total adjusted Fever-Tree revenue came in at £372.7m, up 2% on a reported basis, with the US leading the way at 6% constant currency growth as the group bedded in its distribution partnership with Molson Coors.

The brand is now embedded across roughly 400 regional distributors stateside, and retail sales growth and market share gains were maintained throughout the transition.

The UK was softer, with revenue down 2% to £108.4m. The on-trade remained under pressure from higher labour costs, duty rises, and cautious consumer spending, particularly around gin. Off-trade performance was more encouraging, returning to growth in the second half, with the beyond tonic portfolio up 16% in that channel.

Europe edged 2% higher at constant currency, led by France and Benelux, while the rest of the world surged 22%, boosted by strong contributions from Australia, New Zealand and Canada.

Once known almost exclusively for its tonic water, the company has diversified its product mix and leveraged its brand as consumer tastes evolve. Products beyond tonic now account for 45% of group revenue, with Ginger Beer the standout. Fever-Tree is now the world’s largest ginger beer brand by value.

Adjusted EBITDA fell 16% to £42.4m, reflecting the structural shift to profit-sharing under the Molson Coors model and a £2.8m provision for a potential UK Extended Producer Responsibility levy, which the company is contesting through a formal legal challenge. Stripping out that provision, EBITDA was £45.2m, in line with previous guidance.

The ordinary dividend increased 2% to 17.31p as the group completed a £100m share buyback during the year and has a further £30m programme underway.

Fever-Tree said expectations for 2026 are unchanged and in line with market consensus, despite the uncertain geopolitical backdrop.

FTSE 100 rockets 300 points in minutes as Trump backs down from Iran power plant attacks

The FTSE 100 surged 300 points in minutes on Monday after Donald Trump said that he had ordered the Department of War to hold off striking power facilities after ‘constructive’ talks with Iran.

London’s leading index was down over 2% before Trump posted on social media that the US would postpone attacks on Iranian power plants, with fears of a prolonged oil shock sending waves through markets in the early stages of Monday’s session.

But Trump’s social post sparked a 300-point FTSE 100 rally from lows of 9,670 to 9,980 in a matter of minutes shortly before midday. However, comments from Iran that there was no open dialogue with Trump led to the rally fading.

Chris Beauchamp, Chief Market Analyst at IG, said: “Trump has sprung his usual surprise on markets, pausing strikes on energy infrastructure as a result of successful talks. But this leaves big questions unanswered – Hormuz remains closed, the damage to energy infrastructure is still there and it is unclear whether airstrikes on other targets will continue.

“While this was the headline investors have been hoping for, the fact that Brent has rebounded back above $100 shows that markets remain sceptical.”

Brent Crude oil was trading down 9% at $101.61, while WTI lost 8% to $89.69.

The FTSE 100 was 0.1% higher at 9,934 at the time of writing, with some of the stocks most heavily hit by the conflict among the best performers.

Hopes of a de-escalation in the conflict and the avoidance of a long-term energy shock were well received by interest-rate-sensitive sectors. Housebuilders rallied with Barratt Redrow gaining 3.5%. Persimmon was around 2% to the good.

HSBC rose 2.6% as FTSE 100 banks jumped. Barclays added 2%.

Croda was the FTSE 100’s top riser after Goldman Sachs raised their rating on the stock to a ‘buy’.

BP and Shell were among the biggest detractors as oil prices slid on hopes that the conflict was past its most dangerous point. Both oil majors were down more than 3%.

US futures were pointing to a higher US session, likely to be volatile, driven by any fresh headlines related to the Middle East conflict.

AIM movers: Eroxon Intense hope for Futura Medical and further cash outflow for Blackbird

0

Emissions reduction fuel technology developer Quadrise (LON: QED) had cash of £4m at the end of 2025 having lost £2m in the first half. The MSC vessel and OCP (Morocco) trials are being prepared and there are talks with other ship owners. The share price increased 15.85 to 1.7375p.

Strategic Minerals (LON: SML) will publish a new mineral resource estimate for the Redmoor tungsten tin copper project on Thursday 26 March. There will also be an updated Economic Sensitivity Analysis. The share price rose a further 11% to 6.05p, which is the highest it has been for 13 years.

Futura Medical (LON: FUM) says results of the home user test of Eroxon and prototype Eroxon Intense were positive with an improvement on the previous phase 3 study for Eroxon. The study was over four weeks. Eroxon Intense gives a statistically significant greater sensorial effect over the current Eroxon® formulation. The participants had mild to moderate erectile dysfunction. This helps to target marketing at men under 60 years old with mid to moderate erectile dysfunction. Regulatory authorisation could be achieved is expected in the US and Europe by the end of the first half of 2026. The share price recovered 5.42% to 1.215p.

Metals One (LON: MET1) is focusing on creating a vertically integrated gold business in Sough Africa. It has converted $1.8m of loan notes to take a 30% stake in Lions Bay Resources, which is acquiring a cogeneration plant which may be reconfigured to include a gold concentrate roasting complex. It also plans to buy the assets of Vantage Goldfields, which has mining leases in the Barberton region that have a “historical resource inventory of 4.5 million ounces of gold”. Metals One has been selling its stakes in other AIM-quoted mining companies to raise cash to provide funds to help Lions Bay Resources to progress its deals. The Metals One share price is 4.26% ahead at 1.59p.

FALLERS

Frontier IP (LON: FIPP) investee company Alusid, where it owns 36.2%, has reached an agreement with Netherlands-based FRONT Materials and Tegelgroep Nederland for the distribution of tiles in the Netherlands. The wholesaler has distribution activities in adjoining countries. Initially, Mas floor tiles, using around 95% recycled material, will be stocked. Alusid is assessing the potential of a flotation. The Frontier IP share price slipped 11.85 to 11.25p.

SkinBioTherapeutics (LON: SBTX) shares continue to fall following the announcement at the end of last week that interim results will be delayed. The board investigation is continuing. This means that trading in the shares will be suspended on 1 April. Cash was £2.44m on 19 March. The share price declined 4% to 6p, having been as low as 5.25p.

Shares in Medpal AI (LON: MPAL) slid 9.48% to 2.625p following Friday evening’s placing and retail offer. The placing raised £527,000 at 2.5p/share and a retail offer could raise up to £200,000. The digital health company is entering the home blood testing market with the MedPal weight loss blood test.

Real-time video editing technology developer Blackbird (LON: BIRD) lost contracts and that led to a decline in revenues from £1.61m to £1.38m in 2025. Cash burn was £3.01m after a reduction in costs. There was £2.72m in the bank at the end of 2025 and £500,000 has been subsequently raised. User engagement of elevate.io is improving and the Winter Olympics should have provided a boost to use of the editing technology. The share price dipped 7.32% to 1.9p, which is just above the all-time low.

ImmuPharma (LON: IMM) has raised £469,000 from a retail offer at 6p/share, taking the total raised to £6.5m at 6p/share. ImmuPharma says that there is significant interest from potential licence partners in its autoimmune disease programme P140. The share price fell 7.84% to 4.7p.

Spire Healthcare shares sink as Bridgepoint and Triton walk away

Spire Healthcare (LSE: SPI) has confirmed that talks with both Bridgepoint and Triton over a possible takeover have collapsed, narrowing the field of bidders in what has been a drawn-out strategic review.

The private hospital operator said that conversations with the two private equity firms have ended, but noted that the board remains in discussions with other unnamed parties regarding a potential sale.

Sky News reported last Thursday that Bridgepoint was preparing a 230p-per-share offer for Spire, which sent shares higher on Friday.

But after the market closed, Bridgepoint said it ‘has been unable to get sufficient confidence as to a transaction structure that would work for all stakeholders at this time’.

Triton followed with a statement saying it did not intend to make a firm offer for Spire.

As a result, Spire Healthcare share prices were down 20% at 152p at the time of writing on Monday.

Spire launched a strategic review last year to help unlock greater value for shareholders and may still continue life as a standalone entity if a buyer can’t be found.

Cohort wins AU$21.7m Portuguese Navy satcoms contract

Cohort has announced that its Australian subsidiary EM Solutions has secured an AU$21.7m (circa £11.5m) contract to supply satellite communications terminals to the Portuguese Navy.

The deal covers delivery of EM Solutions’ Cobra and King Cobra terminals for the mid-life upgrade of Portugal’s Vasco da Gama-class frigates alongside a number of new-build programmes, with deliveries running through to 2030.

The contract falls under the M-Frigate Users Group, a multinational cooperative framework, with the Netherlands acting as contracting authority on Portugal’s behalf, a structure that underlines the growing international traction for EM Solutions’ satcoms technology within allied naval programmes.

Andy Thomis, Cohort Chief Executive, said: “This important order affirms EM Solutions’ reputation as a world-leading provider of satellite communication systems. Their cutting-edge technology is trusted by navies across the world for resilient high-speed, long range digital communications. Together with other recent wins across the Group, this contract further underpins our order book and enhances the visibility of future revenues.”

Cohort reported revenues of £128.8m for the six months ending October 2025, an increase of 9% on the same period a year prior.

Applied Nutrition shares fall after warning on H2 revenue

Applied Nutrition shares fell on Monday after confirming a bumper first half, with revenue up 57% to £74.5m and adjusted EBITDA rising 56% to £21.5m, but signalled that the second half will be materially softer as it navigates a more front-loaded trading pattern and disruption in the Middle East.

As a result, the FTSE 250 sports nutrition group maintained its full-year revenue guidance at approximately £140m, implying second-half revenue of around £65.5m, a notable step down from H1 and well below the growth rate seen in the first six months.

Applied Nutrition shares were down 14% at the time of writing.

Management attributed the skew to a better-than-expected peak health and fitness trading period in January and accelerated demand for several new product launches, both of which pulled sales forward.

The group also flagged current disruption to shipping routes and purchasing activity in the Middle East, warning it expects some reduction in volumes into the region during H2.

It says the impact is not enough to alter full-year guidance, but given the group’s plans to push into new geographies across Asia, Latin America, and the Middle East, keeping guidance flat will seem like a downgrade to some investors.

The first-half performance itself was strong across the board. UK like-for-like growth was driven by expanded listings with grocers, health retailers, and discounters, headlined by a first out-licensing deal with Morrisons for a high-protein food range. Latin American sales surged 110% year-on-year, and the reformulated Critical Whey protein posted sales 128% ahead of the prior year period.

Free cash flow conversion did drop sharply, however, falling to 51.3% from 84.0%, with free cash flow declining to £7.9m from £8.9m despite the jump in profitability. Construction has since begun on a new global distribution centre and factory expansion that will lift capacity to support around £300m of annual revenue.

Thomas Ryder, CEO of Applied Nutrition, said: “We have continued to execute against our strategic priorities in the period, with deeper engagement and expanded shelf space with existing customers, new customer wins and entry into new channels, continued international rollout into new geographies, while further progressing the build-out of our D2C offering.”

Metals One pushes forward with South African gold strategy

Metals One has outlined progress in its push to build a vertically integrated gold business in South Africa through Lions Bay Resources (LBR), the joint venture vehicle it shares with TSX-V-listed Lions Bay Capital and the Salamander Mining management team.

The company has advanced the full US$1.8m in convertible loan notes to LBR, which it intends to convert into a 30% stake once LBR completes its acquisition of a cogeneration plant in Newcastle, KwaZulu-Natal.

The plant, independently valued at US$39.6m on a replacement basis, is expected to be settled imminently for just US$1.36m and would require roughly US$4.5m to restart steam and power production.

Crucially, the plant may also be reconfigured to include a gold concentrate roasting complex. Such a move could help reduce shipping concentrate to Asian smelters, which has a big impact on South African producers’ margins.

On the mining side, LBR has agreed a plan in principle with the Business Rescue Practitioner overseeing Vantage Goldfields, which has sat in business rescue since the Lily mine crown pillar collapse in 2016.

Vantage holds mining leases across the Barberton greenstone belt, which includes a historical resource inventory of 4.5 million ounces of gold, a central metallurgical complex, and extensive underground workings.

“With our key partners, the Company’s vertically integrated South African gold business development strategy is now being implemented. LBR has secured the cogeneration plant in Newcastle which could play a key role in unlocking value in our targeted mining assets, including Vantage, as a source of cheap power initially, and as a gold roaster in the longer term,” said Daniel Maling, Managing Director of Metals One.

“Thanks to the tireless efforts of the team at LBR, we now have a plan agreed to acquire the Vantage assets through the Business Rescue process.

“We believe these assets will be potentially transformational for LBR, and to Metals One as a 30% owner, and look forward to providing further updates as the Plant acquisition and Vantage plan progress.

“Metal One’s significant cash and liquid investments held on its balance sheet have enabled it to position itself, and LBR, as front runners in the Vantage Business Rescue process.

“LBR is now in the position of considering several offers for project level financing for the balance of cash required to complete the Vantage asset acquisition and mine startup capital.”

Director deals: Finance director takes advantage of Dotdigital share price fall

Following the interim figures digital and social media services provider Dotdigital (LSE: DOTD) finance director Tom Mullan bought 19,081 shares at an average of 52.202p each. He owns 46,177 shares. He initially acquired 27,096 shares at 74p each after his appointment in April 2025.
Chairman John Conley bought 10,000 shares at 52.556p each. That took his shareholding to 43,000 shares. He bought 10,000 shares at 66p each, 10,000 shares at 64p each and 13,000 shares at 70p each prior to Christmas.
Business
Dotdigital has a Software-as-a-Service based model. The Customer Experience Data Platform ...

AIM weekly movers: Strategic Metals raises cash and improves Redmoor recoveries

0

Karelian Diamond Resources (LON: KDR) raised £290,000 via convertible loans. The conversion price is 1.5p. The share price jumped 87.5% to 0.75p. The cash will finance drilling at Anomaly 5 in Finland and exploration on potential nickel copper platinum group element prospects in Northern Ireland.

Strategic Minerals (LON: SML) is raising £4.7m at 3.5p/share and despite the discount the share price gained 43.4% to 4.7p. A prominent international investor approached the company. The cash will be spent on the Redmoor Tungsten-Tin-Copper project in Cornwall. Following the fundraising, there was news concerning improvements in tungsten and silver recovery. Tungsten recovery is 85.8% and silver recovery is 58.7%. This will boost the forthcoming mineral resource estimate.

Sancus Lending (LON: LEND) has agreed an extension of the redemption date for preference shares from 23 November 2026 to 11 February 2031. They will no longer be at a fixed interest rate of 15% and instead there will be a floating rate. Some will be redesignated as Euro preference. The preference shares holder will also subscribe for £750,000 of bonds. Sancus Lending reported a 2025 pre-tax profit of £1.2m, including gains of £2.6m on buying back some zero dividend preference shares. The share price increased 37.5% to 1.1p.

River Global (LON: RVRG) plans to sell the asset management business it has built up to fully listed Liontrust Asset Management (LON: LIO). The initial consideration will be £7.6m in Liontrust shares, followed by up to £2.1m shares depending on certain revenues being achieved. The deal will also release capital from the business. The Liontrust shares will be distributed to A share holders. The B shares are unaffected. The remaining interest will be a structured 30% interest in Parmenion, which is a high growth investment platform. Shareholders and the FCA have to approve the deal. The A shares jumped 37% to 4.625p, while the B shares improved 5.88% to 36p after director Christopher Mills 325,000 B shares at 34.7077p. Liontrust shares dipped 2.04% to 240p.

FALLERS

Investors were disappointed with drilling news from Wishbone Gold (LON: WSBN), which is also quoted on Aquis, concerning Red Setter project in Western Australia, which is near to the Telfer mine. The share price slumped 54.2% to 30p.

SkinBioTherapeutics (LON: SBTX) says interim results will be delayed so trading in the shares will be suspended on 1 April. This is because the board investigation is continuing. Cash was £2.44m on 19 March. The share price dived 40.5% to 6.25p, which is just above the recent low.

Sound Energy (LON: SOU) has raised £500,000 at 5p/share and secured a €1.3m term loan facility agreement, which has an interest rate of 205 each 120 days. The loan drawn down and interest is payable by the end of 2026. The Tendrara phase 1 Micro-LNG development has fully tested and commissioned the Tendrara gas gathering system. Commercial gas sales could start in the third quarter because of delays in the delivery of equipment for the plant. A joint venture will develop solar power plants in Morocco. The share price slid 32.3% to 5.25p.

CPPGroup (LON: CPP) says it has been told that it will not receive any of the potential $5m deferred consideration for its former business in India. CPPGroup is considering its options, but if it does not receive any cash it will have to raise funding within 12 months. The share price declined 29.1% to 52.5p.

Aquis weekly movers: S-Ventures plans UAV acquisition

VSA Capital (LON: VSA) finance director Galin Ganchev bought an initial 32,833 shares at 3p each. The share price jumped 35% to 3.375p.

S-Ventures (LON: SVEN) is raising up to £2m at 3.5p/share and invest in HDL, a drone technology business. HDL is developing hybrid unmanned aerial vehicles and intends to raise cash from investors to finance progress. S-Ventures will invest up to £1.5m and could take a board position. The share price rebounded 29% to 1p

Hot Rocks Investments (LON: HRIP), unchanged at 1.695p, has reduced its stake in Mendell Helium (LON: MDH) from 6.5% to 4.69%, but the share price rose 11.8% to 4.75p.

Patrick Chophard and Oliver Murphy have stepped down from the Ethtry (LON: ETHY) board and Steve Winfield has returned as an executive director. Ethtry says it plans to “concentrate on building a scalable platform at the intersection of digital infrastructure and next-generation computing, with particular emphasis on opportunities across data centre infrastructure, artificial intelligence and emerging quantum technologies”. There is also an Ethereum treasury policy. The share price increased 3.57% to 0.145p.

FALLERS

Investors were disappointed with drilling news from Wishbone Gold (LON: WSBN) concerning Red Setter project in Western Australia, which is near to the Telfer mine. The share price slumped 54.9% to 30p.

The Probiotix Health (LON: PBX) share price slipped 25.8% to 5.75p ahead of sull year results on 30 March.

Stack BTC (LON: STAK) raised £1.9m at 10p/share, including £94,700 from a retail offer. The cash will be used to fund acquisitions and purchase of Bitcoin. AlbR has been appointed as joint corporate broker. The share price dropped 21.2% to 9.75p.

Sulnox Group (LON: SNOX) says results of an independent laboratory evaluation of Sulnox Eco™ confirmed full compatibility across all fuels tested and showed performance benefits. The share price slid 11.35 to 47p.

Astrid Intelligence (LON: ASTR) has £500,000 of Subnet 71 tokens. The share price declined 10.3% to 0.1525p.

Mustapha and Maya El Khalil have a 7.46% shareholding in Ace Liberty and Stone (LON: ALSP). The share price fell 6.67% to 35p.

B HODL (LON: HODL) has bought one Bitcoin for £53,363. The total holding is 163.487 Bitcoin at an average cost of £82,319 each. The share price slipped 3.23% to 7.5p.

Brewer Shepherd Neame (LON: SHEP) reported flat interim revenues and pre-tax profit of £84.7m and £4.2m respectively. Net debt is £84.7m and a £1m share buyback is planned. The dividend has been raised 3% to 4.5p/share. NAV is 1234p/share. Pubs traded strongly and that offset lower brewing volumes, which fell 6.6% representing a slowdown in the rate of decline. Over 37 weeks the like-for-like growth in retail pub sales it 4.4%, while tenanted pubs are 3% ahead over 35 weeks. Panmure Liberum forecasts a full year pre-tax profit of £7.7m, rising to £8.4m next year. The share price dipped 0.89% to 445p.